Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (7.957)

1

Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA

enthalten in: PharmacoEconomics | 2024

von Lin, S. | Shapouri, S. | Parisé, H. | +4

2

CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells

enthalten in: Cancer biology & therapy | 2024

von Wang, H. | Koob, T. | Fromm, J. | +3

3

TROPION-Breast01 : Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer

enthalten in: Future oncology (London, England) | 2024

von Bardia, A. | Jhaveri, K. | Kalinsky, K. | +21

4

KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC : A multicenter phase 2 trial

enthalten in: Cell reports. Medicine | 2024

von Zhao, Y. | Chen, G. | Li, X. | +9

5

Obinutuzumab-Based Drug-Free Macromolecular Therapeutics Synergizes with Topoisomerase Inhibitors

enthalten in: Macromolecular bioscience | 2024

von Gambles, M. | Sborov, D. | Shami, P. | +2

6

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

enthalten in: The New England journal of medicine | 2024

von Powles, T. | Valderrama, B. | Gupta, S. | +122

7

Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker

enthalten in: Journal of controlled release : official journal of the Controlled Release Society | 2024

von Liubomirski, Y. | Tiram, G. | Scomparin, A. | +18

8

Lung toxicity induced by anti-HER2 antibody - drug conjugates for breast cancer

enthalten in: Critical reviews in oncology/hematology | 2024

von Chai, M. | Li, L. | Wu, H. | +3

9

Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors

enthalten in: Clinical and translational science | 2024

von Robbrecht, D. | Grob, J. | Bechter, O. | +20

10

Elotuzumab : no additional effect in patients with newly diagnosed multiple myeloma

enthalten in: The Lancet. Haematology | 2024

von Tamura, H.

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[796]